Tenet Healthcare Corporation (THC)
NYSE: THC · Real-Time Price · USD
129.60
-7.64 (-5.57%)
At close: Feb 21, 2025, 4:00 PM
130.00
+0.40 (0.31%)
After-hours: Feb 21, 2025, 7:56 PM EST
Tenet Healthcare Stock Forecast
Stock Price Forecast
The 18 analysts with 12-month price forecasts for Tenet Healthcare stock have an average target of 163.94, with a low estimate of 122 and a high estimate of 217. The average target predicts an increase of 26.50% from the current stock price of 129.60.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Tenet Healthcare stock from 18 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 6 | 5 | 5 | 5 |
| Buy | 8 | 9 | 8 | 9 | 10 | 10 |
| Hold | 1 | 1 | 2 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 18 | 16 | 17 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $177 | Buy | Reiterates | $177 | +36.57% | Feb 13, 2025 |
| Barclays | Barclays | Buy Maintains $190 → $161 | Buy | Maintains | $190 → $161 | +24.23% | Feb 13, 2025 |
| Keybanc | Keybanc | Buy Maintains $200 → $185 | Buy | Maintains | $200 → $185 | +42.75% | Jan 7, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $190 → $175 | Strong Buy | Maintains | $190 → $175 | +35.03% | Jan 6, 2025 |
| JP Morgan | JP Morgan | Buy Initiates $175 | Buy | Initiates | $175 | +35.03% | Dec 17, 2024 |
Financial Forecast
Revenue This Year
21.49B
from 20.67B
Increased by 3.99%
Revenue Next Year
22.54B
from 21.49B
Increased by 4.87%
EPS This Year
12.03
from 32.70
Decreased by -63.20%
EPS Next Year
13.31
from 12.03
Increased by 10.65%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 23.0B | 24.1B | 25.0B | ||
| Avg | 21.5B | 22.5B | 24.1B | ||
| Low | 20.3B | 21.3B | 23.3B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 11.3% | 12.3% | 10.9% | ||
| Avg | 4.0% | 4.9% | 6.7% | ||
| Low | -1.8% | -0.8% | 3.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 13.57 | 15.19 | 17.76 | ||
| Avg | 12.03 | 13.31 | 15.33 | ||
| Low | 9.65 | 10.78 | 12.33 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -58.5% | 26.3% | 33.4% | ||
| Avg | -63.2% | 10.6% | 15.1% | ||
| Low | -70.5% | -10.4% | -7.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.